Skip to content

COLchicine and Thiamine in Heart Failure due to Ischemic Heart Disease (COLT-HF)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506675-96-00
Acronym
PHRI.COLT-HF
Enrollment
300
Registered
2024-10-30
Start date
2025-01-23
Completion date
Unknown
Last updated
2025-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Colchicine arm: Composite of CV death, HF event, or ischemic CV event (defined as myocardial infarction, ischemic stroke, or arterial revascularization), Thiamine arm: Composite of CV death or HF event

Detailed description

All cause death, hospitalization, Serious adverse events, Side effects or adverse events resulting in study drug discontinuation

Interventions

DRUGBenerva 300 mg compresse gastroresistenti
DRUGPlacebo tablet matching Colchicina

Sponsors

Hamilton Health Sciences Corporation
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Colchicine arm: Composite of CV death, HF event, or ischemic CV event (defined as myocardial infarction, ischemic stroke, or arterial revascularization), Thiamine arm: Composite of CV death or HF event

Secondary

MeasureTime frame
All cause death, hospitalization, Serious adverse events, Side effects or adverse events resulting in study drug discontinuation

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026